Chitosan/Orthobiologics Biomaterials for Regenerative Medicine

该项目的主要目标是设计和创造生物材料，以改善肌肉骨骼疾病的治疗，这些疾病影响着全球17亿人。由蒙特利尔理工学院发明的Ortho-R技术于2015年被Ortho Regenerative Technologies Inc(Ortho RTI)收购，自那以来，这两家实体一直在合作开发该技术。一项修复撕裂肌腱的临床研究已于2022年在美国开始。为了进一步推动Ortho-R技术的发展，需要进行研发工作。该公司还计划探索Ortho-R的新适应症，并为再生医学开发新的生物材料。目标适应症是软组织(肌腱、半月板、软骨、韧带)的修复/再生，以满足在很大程度上未得到满足的主要医疗需求。该项目的目标是A)优化Ortho-R的制造工艺，B)阐明通过Ortho-R处理获得的修复组织的作用模式和结构/机械性能，C)评估Ortho-R用于韧带修复的潜力，以及D)开发性能得到改善的新的生物材料。该研究项目将在再生医学领域产生新技术和新知识产权。该项目将使Ortho RTI继续开发Ortho-R并开发新的生物材料，以扩大其产品组合。除了培训Biomentum公司未来的员工外，它还将产生新的标准化机械测试。最终，生物材料生产和分析方法方面的新技术将为KABS实验室和CERASP创造就业机会。将在前景看好的生命科学领域创造约20个高薪专业/专业职位，并将在专业工作/培训环境中培训高素质人员(&gt；35人)。这一大型项目将使加拿大有可能解决在很大程度上未得到满足的主要医疗需求，并将加强加拿大在生命科学领域的领先地位，同时为该国的经济增长做出贡献。

The main goal of the project is to design and create biomaterials to improve treatment of musculoskeletaldisorders, which affect 1.7 billion people globally. The Ortho-R technology, invented at PolytechniqueMontreal, was acquired in 2015 by Ortho Regenerative Technologies Inc (Ortho RTI), and the 2 entities havesince collaborated to pursue its development. A clinical study for the repair of torn tendons has begun in 2022in the United States. R&D work is required to further advance the Ortho-R technology. The company alsowishes to explore new indications for Ortho-R and develop new biomaterials for regenerative medicine. Thetargeted indications are the repair/regeneration of soft tissues (tendon, meniscus, cartilage, ligament), in order to address major medical needs that are largely unmet. The objectives of the project are A) to optimize the manufacturing processes of Ortho-R, B) to elucidate the modes of action and to characterize the structural/mechanical properties of the repair tissues obtained with Ortho-R treatment, C) to assess the potential of Ortho-R for the repair of ligaments and D) to develop new biomaterials with improved properties. This research project will generate new technologies and new intellectual property in the field of regenerative medicine.This project will allow Ortho RTI to continue the development of Ortho-R and to develop new biomaterialsto expand its product portfolio. It will also generate new standardized mechanical tests, in addition to trainingfuture employees of the company Biomomentum. Eventually, new know-how in biomaterial production andanalytical methods will lead to job creation at KABS Laboratories and CERASP. Around 20 highlyspecialized/paid jobs in the promising field of life sciences will be created and highly qualified personnel (>35)will be trained in a professional working/training environment. This large-scale project will make it possible toaddress major medical needs that are largely unmet and will strengthen Canada's leading position in lifesciences while contributing to the country's economic growth.